Thanks to a strong first quarter, radiation oncology firm Nucletron is increasing its outlook for 2011.
The company said it now expects to realize double-digit sales growth, with earnings before interest, taxes, depreciation, and amortization (EBITDA) projected to rise by a minimum of 20%.